Mito
Member
- Joined
- Dec 10, 2016
- Messages
- 2,554
“A commonly used drug called fluvoxamine was recently tested as a treatment for COVID-19 in the United States. The 152 patients enrolled in the trial had been confirmed to have COVID-19 using a PCR test, and had seen symptoms appear within the past seven days.
Patients who already required COVID-19 hospitalisation, or who had an underlying lung condition, congestive heart failure or other immune conditions, were excluded. The study looked only at those who at the time had a relatively mild form of the disease.
Among these patients, the study found that taking fluvoxamine reduced the incidence of developing a serious COVID-19 condition over a 15-day period. None of the 80 patients treated with fluvoxamine deteriorated, whereas six (8.3%) of the 72 patients given a placebo saw their condition get worse. Their symptoms included shortness of breath, pneumonia and reduced blood oxygen.”
“Thus, it is likely that the effect seen with fluvoxamine in COVID-19 patients has nothing to do with serotonin but everything to do with inhibiting the inflammatory response through the S1R. We know from studies in mice that fluvoxamine can decrease a sepsis-induced inflammatory response and the toxicity that comes with it.”
Patients who already required COVID-19 hospitalisation, or who had an underlying lung condition, congestive heart failure or other immune conditions, were excluded. The study looked only at those who at the time had a relatively mild form of the disease.
Among these patients, the study found that taking fluvoxamine reduced the incidence of developing a serious COVID-19 condition over a 15-day period. None of the 80 patients treated with fluvoxamine deteriorated, whereas six (8.3%) of the 72 patients given a placebo saw their condition get worse. Their symptoms included shortness of breath, pneumonia and reduced blood oxygen.”
“Thus, it is likely that the effect seen with fluvoxamine in COVID-19 patients has nothing to do with serotonin but everything to do with inhibiting the inflammatory response through the S1R. We know from studies in mice that fluvoxamine can decrease a sepsis-induced inflammatory response and the toxicity that comes with it.”
Why an antidepressant could be used to treat COVID-19
Fluvoxamine has shown positive results in early trials.
theconversation.com
Effect of Fluvoxamine vs Placebo on Clinical Deterioration in Outpatients With Symptomatic COVID-19
This randomized trial compares the effects of fluvoxamine, a selective serotonin reuptake inhibitor with immunomodulatory effects vs placebo on a composite of dyspnea or pneumonia and oxygen desaturation among adult outpatients with polymerase chain reaction–confirmed mild coronavirus disease...
jamanetwork.com